T‐cell regulation of neutrophil infiltrate at the early stages of a murine colitis model
暂无分享,去创建一个
B. Lambrecht | L. V. van Rijt | C. de Haar | J. Samsom | E. Nieuwenhuis | J. Escher | Y. Simons‐Oosterhuis | D. Lindenbergh‐Kortleve | P. V. van Lierop | Pieter P. E. van Lierop | Leonie S van Rijt
[1] D. Cohen,et al. Suppression of experimental colitis in mice by CD11c+ dendritic cells , 2009, Inflammatory bowel diseases.
[2] E. Kuipers,et al. Local application of tacrolimus in distal colitis: Feasible and safe , 2009, Inflammatory bowel diseases.
[3] J. Calixto,et al. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice , 2008, Journal of leukocyte biology.
[4] B. Feagan,et al. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. , 2008, The Cochrane database of systematic reviews.
[5] Judy H. Cho,et al. Chronic stimulation of Nod2 mediates tolerance to bacterial products , 2007, Proceedings of the National Academy of Sciences.
[6] Sukgil Song,et al. Calcineurin Inhibitors Block MHC-Restricted Antigen Presentation In Vivo1 , 2007, The Journal of Immunology.
[7] R. Blumberg,et al. The role of the epithelial barrier in inflammatory bowel disease. , 2006, Advances in experimental medicine and biology.
[8] Jane E. Dalton,et al. Intraepithelial γδ+ Lymphocytes Maintain the Integrity of Intestinal Epithelial Tight Junctions in Response to Infection , 2006 .
[9] T. Matsui,et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis , 2006, Gut.
[10] J. Escher,et al. Defective acute inflammation in Crohn's disease , 2006, The Lancet.
[11] J. Kolls,et al. Critical role of IL‐17 receptor signaling in acute TNBS‐induced colitis , 2006, Inflammatory bowel diseases.
[12] E. Kuipers,et al. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: Their mechanisms of action and role in the treatment of IBD , 2006, Inflammatory bowel diseases.
[13] J. Korzenik,et al. Evolving knowledge and therapy of inflammatory bowel disease , 2006, Nature Reviews Drug Discovery.
[14] William D. Lees,et al. Defective acute inflammation in Crohn's disease: a clinical investigation , 2006, The Lancet.
[15] W. Hop,et al. Chemokine Production by Buccal Epithelium as a Distinctive Feature of Pediatric Crohn Disease , 2006, Journal of pediatric gastroenterology and nutrition.
[16] Jane E. Dalton,et al. Intraepithelial gammadelta+ lymphocytes maintain the integrity of intestinal epithelial tight junctions in response to infection. , 2006, Gastroenterology.
[17] R. Pieters,et al. Methotrexate-induced mucositis in mucin 2-deficient mice. , 2006, Journal of cellular physiology.
[18] J. Garssen,et al. New cohorts of naive T cells exacerbate ongoing allergy but can be suppressed by regulatory T cells , 2005, Allergy.
[19] A. Ishizaka,et al. Tacrolimus (FK506) has protective actions against murine bleomycin-induced acute lung injuries. , 2005, European journal of pharmacology.
[20] Elke Cario,et al. Intestinal epithelial TOLLerance versus inTOLLerance of commensals. , 2005, Molecular immunology.
[21] Michael Karin,et al. Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing , 2005, Science.
[22] M Schwab,et al. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression , 2004, Gut.
[23] S. Kunkel,et al. The role of CCL3/macrophage inflammatory protein-1α in experimental colitis , 2004 .
[24] Tomohiro Watanabe,et al. NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses , 2004, Nature Immunology.
[25] S. Kunkel,et al. The role of CCL3/macrophage inflammatory protein-1alpha in experimental colitis. , 2004, European journal of pharmacology.
[26] J. Samsom,et al. Early Events in Peripheral Regulatory T Cell Induction via the Nasal Mucosa , 2003, The Journal of Immunology.
[27] Judy H. Cho,et al. Expression of NOD2 in Paneth cells: a possible link to Crohn’s ileitis , 2003, Gut.
[28] W. Petritsch,et al. Effect of oral tacrolimus (FK 506) on steroid‐refractory moderate/severe ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.
[29] R. Hershberg,et al. Delineation of a CD1d-restricted antigen presentation pathway associated with human and mouse intestinal epithelial cells. , 2003, Gastroenterology.
[30] H. Büller,et al. Treatment of inflammatory bowel disease in childhood: best available evidence. , 2003, Inflammatory bowel diseases.
[31] M. Neurath,et al. Disruption of T helper 2-immune responses in Epstein–Barr virus-induced gene 3-deficient mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[32] V. Koteliansky,et al. Importance of Innate Immunity and Collagen Binding Integrin α1β1 in TNBS-Induced Colitis , 2002 .
[33] K. Fellermann,et al. Response of Refractory Colitis to Intravenous or Oral Tacrolimus (FK506) , 2002, Inflammatory bowel diseases.
[34] Steffen Jung,et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. , 2002, Immunity.
[35] E. Moilanen,et al. Calcineurin inhibitors, cyclosporin A and tacrolimus inhibit expression of inducible nitric oxide synthase in colon epithelial and macrophage cell lines. , 2002, European journal of pharmacology.
[36] A. Vandewalle,et al. Lamina Propria CD4+ T Lymphocytes Synergize with Murine Intestinal Epithelial Cells to Enhance Proinflammatory Response Against an Intracellular Pathogen1 , 2002, The Journal of Immunology.
[37] C. Elson,et al. T Helper 1 and T Helper 2 Cells Are Pathogenic in an Antigen-specific Model of Colitis , 2002, The Journal of experimental medicine.
[38] V. Koteliansky,et al. Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. , 2002, Immunity.
[39] R. Blumberg,et al. The immunology of mucosal models of inflammation. , 2002, Annual review of immunology.
[40] J. Raemaekers,et al. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. , 2001, The Journal of molecular diagnostics : JMD.
[41] A. Griffiths,et al. Oral tacrolimus treatment of severe colitis in children. , 2000, The Journal of pediatrics.
[42] W. Strober,et al. Treatment of Experimental (Trinitrobenzene Sulfonic Acid) Colitis by Intranasal Administration of Transforming Growth Factor (Tgf)-β1 Plasmid , 2000, The Journal of Experimental Medicine.
[43] K. Nakamura,et al. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. , 2000, The Journal of experimental medicine.
[44] L. Mayer,et al. The intestinal epithelial cell: processing and presentation of antigen to the mucosal immune system , 1999, Immunological reviews.
[45] P. Kubes,et al. Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice , 1999, Gut.
[46] M. Neurath,et al. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. , 1999, Gastroenterology.
[47] L. Boscá,et al. Protective effect of cyclosporin A and FK506 from nitric oxide‐dependent apoptosis in activated macrophages , 1999, British journal of pharmacology.
[48] T. Denning,et al. Expression of the neutrophil chemokine KC in the colon of mice with enterocolitis and by intestinal epithelial cell lines: effects of flora and proinflammatory cytokines. , 1999, Journal of immunology.
[49] A. Weaver,et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. , 1999, Inflammatory bowel diseases.
[50] O. Wijburg,et al. CD4+ T cells from 2,4,6‐trinitrobenzene sulfonic acid (TNBS)‐induced colitis rodents migrate to the recipient's colon upon transfer; down‐regulation by CD8+ T cells , 1998, Clinical and experimental immunology.
[51] J. Mcghee,et al. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. , 1996, Journal of immunology.
[52] M. Neurath,et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice , 1995, The Journal of experimental medicine.
[53] F. Powrie,et al. T cells in inflammatory bowel disease: protective and pathogenic roles. , 1995, Immunity.
[54] S. Tonegawa,et al. Homeostatic regulation of intestinal epithelia by intraepithelial gamma delta T cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[55] T. Ozawa,et al. Effects of FK506 on an experimental model of colitis in rats , 1995, Alimentary pharmacology & therapeutics.
[56] H. Asakura,et al. Activated immunocompetent cells in rat colitis mucosa induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506. , 1995, Digestion.
[57] K. Leclair,et al. Induction of IL-8 expression in T cells uses the CD28 costimulatory pathway. , 1994, Journal of immunology.
[58] M. Kagnoff,et al. Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry , 1993, Infection and immunity.
[59] N. Sigal,et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. , 1990, Journal of immunology.
[60] B. Kahan. Drug therapy: cyclosporine , 1989 .